[Ofatumumab in the treatment of multiple sclerosis - A summary of preclinical and clinical data].
| Autor: | Klehmet J; Klinik für Neurologie, Zentrum für Multiple Sklerose, Jüdisches Krankenhaus Berlin, Berlin, Germany., Bopp T; Institut für Immunologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany.; Forschungszentrum für Immuntherapie (FZI), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany. |
|---|---|
| Jazyk: | němčina |
| Zdroj: | Fortschritte der Neurologie-Psychiatrie [Fortschr Neurol Psychiatr] 2024 Aug 19. Date of Electronic Publication: 2024 Aug 19. |
| DOI: | 10.1055/a-2365-0966 |
| Abstrakt: | Background: B-cell targeted therapies are highly effective in multiple sclerosis (MS). Most of these therapies are administered intravenously at long intervals. Ofatumumab, an anti-CD20 antibody that is administered subcutaneously at low doses on a monthly basis due to its high affinity to the target structure, became available for the treatment of MS in 2021. Methods: An overview of practice-relevant immunological and clinical data on ofatumumab is provided. Results: The high affinity of ofatumumab to the target structure allows low dose and low volume administration, with the release and absorption profile after subcutaneous application allowing for high concentrations in the lymph nodes and gradual depletion of B-cells. Rapid onset of action is achieved as well as B-cell repletion within a few months in case of discontinuation of therapy. Long-term data show stable IgG levels over up to four years and high efficacy with respect to relapse rate, progression, and cognition. According to current study data, the effect compared to teriflunomide is greater the earlier therapy is initiated. Ofatumumab has a specific B-cell depletion pattern. CD20 expressing B-cell progenitor cells in the bone marrow are preserved and therefore also the inducibility and differentiation of plasma cells. The formation of a humoral immunological memory is therefore possible. Four-year study data showed no abnormalities in the rate of severe infections or malignancies. Conclusions: Ofatumumab is an innovative B-cell targeted therapy. It is highly effective with a good safety and tolerability profile, well controllable and maintains immunocompetence against pathogens. Competing Interests: JK hat persönliche Kompensationsleistungen von Merck Serono, Biogen, Novartis, TEVA, Roche, Sanofi/Genzyme, Celgene/ Bristol Myers Squibb und Janssen erhalten.TB hat persönliche Kompensationsleistungen von AstraZeneca, Merck Serono, Biogen, Novartis, TEVA, Roche, Sanofi/Genzyme, Celgene/ Bristol Myers Squibb, Pathios Therapeutics und Janssen erhalten. (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|